<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507597</url>
  </required_header>
  <id_info>
    <org_study_id>GlukaStase</org_study_id>
    <secondary_id>H-3-2011-088</secondary_id>
    <nct_id>NCT01507597</nct_id>
  </id_info>
  <brief_title>The Effect of GLP-1 on the Inhibition of Glucagon Secretion</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes(both types) are recognized by high levels of glucagon in the circulation.

      Glucagon is known to increase blood glucose, and might therefore contribute to the respective
      diseases. Under some circumstances the gut hormone GLP-1 inhibits the glucagon secretion.

      The investigators aim to identify the impact of GLP-1 on the glucagon secretion, at
      increasing blood glucose levels in healthy subjects, in patients with type 2 diabetes, and in
      patients with type 1 diabetes.

      The investigators think that the effect of GLP-1 on the glucagon secretion might be dependent
      of blood glucose levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Glucagon response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma GLP-1 response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Glucose response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>at 0, 120, and 180 min</time_frame>
    <description>Assessed by indirect calorimetry during the GLP-1 infusion / glucose clamp-session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger scores response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>Assessed by VAS during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Insulin response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma GIP response to the GLP-1 infusion / glucose clamp</measure>
    <time_frame>At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min</time_frame>
    <description>The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Intake</measure>
    <time_frame>at 210 min</time_frame>
    <description>Assessed by ad'libitum meal after the 210 min GLP-1 infusion / glucose clamp.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Native human Glucagon-like Peptide-1 ( GLP-1(7-36))</intervention_name>
    <description>Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>T1DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>T1DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Native human Glucagon-like Peptide-1 ( GLP-1(7-36))</intervention_name>
    <description>Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>T1DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Native human Glucagon-like Peptide-1 ( GLP-1(7-36))</intervention_name>
    <description>Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>T1DM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with T2DM

          -  Above the age of 35 years, treatment with diet or oral anti-diabetic medication.
             Diagnosed with T2DM in at leat three months in advance(WHO criterion)

          -  Normal hemoglobin

          -  Informed content Patients with T1DM

          -  T1DM (WHO criterion)

          -  Plasma-C-peptid negative due to arginin-test

          -  Normal hemoglobin

          -  age&gt; 18 years

          -  Informed content Healthy subjects

          -  Normal fasting plasma glucose and normal glucose tolerance (WHO criterion)

          -  Normal hemoglobin

          -  Age &gt;18 years

          -  Informed content

        Exclusion Criteria:

        Patients with T2DM

          -  Treatment with glitazones and/or gliptins

          -  Inflammatory bowels disease

          -  previous bowel resection with or without stomy

          -  Nephropathy (serum creatinin &gt;150 µM and/or albuminuria)

          -  Liver disease (serum alanine-aminotransferase (ALAT) and/or serum
             aspartate-aminotransferase (ASAT) &gt;2×normal values)

          -  Medical treatment impossible to break for 12h.

          -  Age &gt;80 years Patients with T1DM

          -  Overweight (BMI &gt;30 kg/m2)

          -  Inflammatory bowels disease

          -  previous bowel resection with or without stomy

          -  Nephropathy (serum creatinin &gt;150 µM and/or albuminuria)

          -  Liver disease (serum alanine-aminotransferase (ALAT) and/or serum
             aspartate-aminotransferase (ASAT) &gt;2×normal values)

          -  Medical treatment impossible to break for 12h (except treatment with insulin).

          -  Age &gt;80 years

        Healthy subjects

          -  Diabetes

          -  Prediabetes (impaired glucose tolerance and/or impaired fasting plasma glucose)

          -  First order relatives with diabetes

          -  Overweight (BMI &gt;30 kg/m2)

          -  Inflammatory bowels disease

          -  previous bowel resection with or without stomy

          -  Nephropathy (serum creatinin &gt;150 µM and/or albuminuria)

          -  Liver disease (serum alanine-aminotransferase (ALAT) and/or serum
             aspartate-aminotransferase (ASAT) &gt;2×normal values)

          -  Medical treatment impossible to break for 12h.

          -  Age &gt;80 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2012</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jonatan I Bagger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Normal physiology</keyword>
  <keyword>T2DM</keyword>
  <keyword>T1DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

